The stock price of ) fell by 2.1% in mid-day trading Thursday. Stock traded as low at GBX 32 ($0.41), and traded last at GBX33.30 ($0.42). Trading saw 304,688 share changes hands, which is a 24% decrease from the 400,298 average session volume. The stock closed previously at GBX34 ($0.42).
Analyst Upgrades and downgrades
The company has a moving average 50-day of GBX32.73, and a moving average 200-day of GBX40.12. The market cap is PS31.46m, the PE ratio is -370.00, and beta is 0.33.
Destiny Pharma: Insiders' Guide to Buying and selling
Insider Nick Rodgers bought 20,000 shares in the company's stock on Monday, 27th February. Stock was purchased at an average of GBX34 ($0.42) per shares, for a transaction total of PS6,800 (8,495.75). Insiders own 18.85% of shares.
Destiny Pharma Company Overview
Destiny Pharma plc is a biotechnology firm that focuses on discovering, developing, and marketing medicines to treat infectious diseases. The company is developing NTCD M3 which is currently in Phase III of clinical trials for the prevention and treatment of recurrent Clostridioides difficile infections. XF 73 Nasal is also in Phase II of clinical trials for the prevention and treatment of post-surgical staphylococcal infections.
MarketBeat.com offers a FREE daily email newsletter